Eli Lilly ROA 2006-2018 | LLY

Current and historical return on assets (ROA) values for Eli Lilly (LLY) over the last 10 years.
Eli Lilly Annual ROA - Return on Assets
2017 -0.45
2016 7.06
2015 6.77
2014 6.58
2013 13.29
2012 11.89
2011 12.92
2010 16.35
2009 15.76
2008 -7.09
2007 10.99
2006 12.13
2005 8.14
Eli Lilly Quarterly ROA - Return on Assets
Q2 2018 -0.61
Q1 2018 2.75
Q4 2017 -3.68
Q3 2017 1.29
Q2 2017 2.46
Q1 2017 -0.30
Q4 2016 1.99
Q3 2016 2.07
Q2 2016 2.05
Q1 2016 1.27
Q4 2015 1.35
Q3 2015 2.20
Q2 2015 1.67
Q1 2015 1.49
Q4 2014 1.18
Q3 2014 1.45
Q2 2014 2.10
Q1 2014 2.09
Q4 2013 2.06
Q3 2013 3.54
Q2 2013 3.63
Q1 2013 4.79
Q4 2012 2.41
Q3 2012 3.87
Q2 2012 2.90
Q1 2012 3.14
Q4 2011 2.55
Q3 2011 3.74
Q2 2011 3.65
Q1 2011 3.33
Q4 2010 3.77
Q3 2010 4.36
Q2 2010 4.87
Q1 2010 4.59
Q4 2009 3.33
Q3 2009 3.47
Q2 2009 4.30
Q1 2009 4.94
Q4 2008 -12.42
Q3 2008 -1.68
Q2 2008 3.46
Q1 2008 3.91
Q4 2007 3.18
Q3 2007 3.71
Q2 2007 2.76
Q1 2007 2.14
Q4 2006 0.60
Q3 2006 3.65
Q2 2006 3.36
Q1 2006 3.46
Q4 2005 2.94
Q3 2005 3.20
Q2 2005 -1.08
Q1 2005 3.17
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $110.019B $22.871B
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $349.368B 16.69
Pfizer (PFE) United States $242.936B 14.22
Novartis AG (NVS) Switzerland $191.051B 16.39
Merck (MRK) United States $179.890B 15.89
AbbVie (ABBV) United States $146.551B 14.32
Novo Nordisk (NVO) Denmark $115.579B 18.48
Sanofi (SNY) France $104.111B 13.18
AstraZeneca (AZN) United Kingdom $98.834B 10.87
GlaxoSmithKline (GSK) United Kingdom $98.627B 13.17
Bristol-Myers Squibb (BMY) United States $97.124B 17.58